EUVIMEDEUVIMED entdecken
Übersichtsarbeit

From lymphopenia to restoration: IL-7 immunotherapy for lymphocyte recovery in glioblastoma

Joonseok Kim, Haeyoun Choi, Sin-Soo Jeun, Stephen Ahn

Cancer Letters · 2024

DOI: 10.1016/j.canlet.2024.216714 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Letters, 2024. Verfasst von Joonseok Kim und 3 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Glioblastoma, Lymphopenia. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 77 Literaturangaben. Gefördert von: National Research Foundation of Korea, Ministry of Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma, the most prevalent malignant primary brain tumor, presents substantial treatment challenges because of its inherent aggressiveness and limited therapeutic options. Lymphopenia, defined as reduced peripheral blood lymphocyte count, commonly occurs as a consequence of the disease and its treatment. Recent studies have associated lymphopenia with a poor prognosis. Factors that contribute to lymphopenia include radiotherapy, chemotherapy, and the tumor itself. Patients who are female, older, using dexamethasone, or receiving higher doses of radiation therapy are particularly vulnerable to this condition. Several preclinical studies have explored the use of interleukin-7, a crucial cytokine for lymphocyte homeostasis, to restore lymphocyte counts and potentially rebuild the immune system to combat glioblastoma cells. With the development of recombinant interleukin-7 for prolonged activity in the body, various clinical trials are underway to explore this treatment in patients with glioblastoma. Our study provides a comprehensive summary of the incidence of lymphopenia, its potential biological background, and the associated clinical risk factors. Furthermore, we reviewed several clinical trials using IL-7 cytokine therapy in glioblastoma patients. We propose IL-7 as a promising immunotherapeutic strategy for glioblastoma treatment. We are optimistic that our study will enhance understanding of the complex interplay between lymphopenia and glioblastoma and will pave the way for the development of more effective treatment modalities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaLymphopeniaHumansFemaleMaleInterleukin-7LymphocytesImmunotherapy

Stichwörter der Autor:innen

GlioblastomaImmunotherapyInterleukin-7Lymphopenia

Substanzen

Interleukin-7

Autor:innen und Institutionen

  • College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
  • Department of Microbiology, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
  • Department of Neurosurgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
  • Department of Neurosurgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. Electronic address: nsstp@catholic.ac.kr.

Förderung

  • National Research Foundation of Korea
  • Ministry of Education

Zitieren

APA

Kim, J., Choi, H., Jeun, S. S., & Ahn, S. (2024). From lymphopenia to restoration: IL-7 immunotherapy for lymphocyte recovery in glioblastoma. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.216714

Vancouver

Kim J, Choi H, Jeun SS, Ahn S. From lymphopenia to restoration: IL-7 immunotherapy for lymphocyte recovery in glioblastoma. Cancer Letters. 2024. doi:10.1016/j.canlet.2024.216714

BibTeX
@article{Kim2024,
  author = {Kim, Joonseok and Choi, Haeyoun and Jeun, Sin-Soo and Ahn, Stephen},
  title = {From lymphopenia to restoration: IL-7 immunotherapy for lymphocyte recovery in glioblastoma},
  journal = {Cancer Letters},
  year = {2024},
  doi = {10.1016/j.canlet.2024.216714}
}
Kostenlos starten →